Promyelocytic leukemia protein is a cell-intrinsic factor inhibiting parvovirus DNA replication

Journal of Virology

Volumn 88, Issue 2, 2014, Pages 925-936

  Mitchell, Angela M ^a   Hirsch, Matthew L ^a   Li, Chengwen ^a   Jude Samulski, R ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PARVOVIRUS VECTOR; PROMYELOCYTIC LEUKEMIA PROTEIN; PROMYELOCYTIC LEUKEMIA PROTEIN 2; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VIRUS DNA;

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DNA REPLICATION; DNA SYNTHESIS; EXPRESSION VECTOR; FEMALE; GENE OVEREXPRESSION; GENETIC CONSERVATION; HUMAN; HUMAN CELL; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; SEX DIFFERENCE; VIRAL GENE DELIVERY SYSTEM; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS RECOMBINANT; VIRUS REPLICATION; WILD TYPE;

ANIMALS; CELL LINE; DEPENDOVIRUS; DNA REPLICATION; DOWN-REGULATION; FEMALE; HUMANS; MALE; MICE, 129 STRAIN; MICE, KNOCKOUT; NUCLEAR PROTEINS; PARVOVIRIDAE INFECTIONS; RECOMBINATION, GENETIC; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS; VIRUS REPLICATION;

EID: 84891687081     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02922-13     Document Type: Article

References (49)

1. Xiao X, Xiao W, Li J, Samulski RJ. 1997. A novel 165-base-pair terminal repeat sequence is the sole cis requirement for the adeno-associated virus life cycle. J. Virol. 71:941-948.
2. Simonelli F, Maguire AM, Testa F, Pierce EA, Mingozzi F, Bennicelli JL, Rossi S, Marshall K, Banfi S, Surace EM, Sun J, Redmond TM, Zhu X, Shindler KS, Ying G-S, Ziviello C, Acerra C, Wright JF, McDonnell JW, High KA, Bennett J, Auricchio A. 2010. Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol. Ther. 18:643-650. http://dx.doi.org/10.1038/mt.2009.277.
3. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ, Ozelo MC, Hoots K, Blatt P, Konkle B, Dake M, Kaye R, Razavi M, Zajko A, Zehnder J, Rustagi PK, Nakai H, Chew A, Leonard D, Wright JF, Lessard RR, Sommer JM, Tigges M, Sabatino D, Luk A, Jiang H, Mingozzi F, Couto L, Ertl HC, High KA, Kay MA. 2006. Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat. Med. 12:342-347. http://dx.doi.org/10.1038/nm1358.
4. Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC, Chowdary P, Riddell A, Pie AJ, Harrington C, O'Beirne J, Smith K, Pasi J, Glader B, Rustagi P, Ng CY, Kay MA, Zhou J, Spence Y, Morton CL, Allay J, Coleman J, Sleep S, Cunningham JM, Srivastava D, Basner-Tschakarjan E, Mingozzi F, High KA, Gray JT, Reiss UM, Nienhuis AW, Davidoff AM. 2011. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N. Engl. J. Med. 365:2357-2365. http://dx.doi.org/10.1056/NEJMoa1108046.
5. Mitchell AM, Nicolson SC, Warischalk JK, Samulski RJ. 2010. AAV's anatomy: roadmap for optimizing vectors for translational success. Curr. Gene Ther. 10:319-340. http://dx.doi.org/10.2174/156652310793180706.
6. Xiao W, Warrington KH, Jr, Hearing P, Hughes J, Muzyczka N. 2002. Adenovirus-facilitated nuclear translocation of adeno-associated virus type 2. J. Virol. 76:11505-11517. http://dx.doi.org/10.1128/JVI.76.22.11505-11517.2002.
7. Shi Y, Seto E, Chang LS, Shenk T. 1991. Transcriptional repression by YY1, a human GLI-Kruppel-related protein, and relief of repression by adenovirus E1A protein. Cell 67:377-388. http://dx.doi.org/10.1016/0092-8674(91)90189-6.
8. Geoffroy M-C, Salvetti A. 2005. Helper functions required for wild type and recombinant adeno-associated virus growth. Curr. Gene Ther. 5:265-271. http://dx.doi.org/10.2174/1566523054064977.
9. Geoffroy MC, Chelbi-Alix MK. 2011. Role of promyelocytic leukemia protein in host antiviral defense. J. Interferon Cytokine Res. 31:145-158. http://dx.doi.org/10.1089/jir.2010.0111.
10. Diaz-Griffero F, Qin XR, Hayashi F, Kigawa T, Finzi A, Sarnak Z, Lienlaf M, Yokoyama S, Sodroski J. 2009. A B-box 2 surface patch important for TRIM5alpha self-association, capsid binding avidity, and retrovirus restriction. J. Virol. 83:10737-10751. http://dx.doi.org/10.1128/JVI.01307-09.
11. Mallery DL, McEwan WA, Bidgood SR, Towers GJ, Johnson CM, James LC. 2010. Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21). Proc. Natl. Acad. Sci. U. S. A. 107:19985-19990. http://dx.doi.org/10.1073/pnas.1014074107.
12. McNab FW, Rajsbaum R, Stoye JP, O'Garra A. 2011. Tripartite-motif proteins and innate immune regulation. Curr. Opin. Immunol. 23:46-56. http://dx.doi.org/10.1016/j.coi.2010.10.021.
13. Condemine W, Takahashi Y, Zhu J, Puvion-Dutilleul F, Guegan S, Janin A, de The H. 2006. Characterization of endogenous human promyelocytic leukemia isoforms. Cancer Res. 66:6192-6198. http://dx.doi.org/10.1158/0008-5472.CAN-05-3792.
14. Lang M, Jegou T, Chung I, Richter K, Munch S, Udvarhelyi A, Cremer C, Hemmerich P, Engelhardt J, Hell SW, Rippe K. 2010. Threedimensional organization of promyelocytic leukemia nuclear bodies. J. Cell Sci. 123:392-400. http://dx.doi.org/10.1242/jcs.053496.
15. Chelbi-Alix MK, Quignon F, Pelicano L, Koken MH, de The H. 1998. Resistance to virus infection conferred by the interferon-induced promyelocytic leukemia protein. J. Virol. 72:1043-1051.
16. Regad T, Saib A, Lallemand-Breitenbach V, Pandolfi PP, de The H, Chelbi-Alix MK. 2001. PML mediates the interferon-induced antiviral state against a complex retrovirus via its association with the viral transactivator. EMBO J. 20:3495-3505. http://dx.doi.org/10.1093/emboj/20.13.3495.
17. McNally BA, Trgovcich J, Maul GG, Liu Y, Zheng P. 2008. A role for cytoplasmic PML in cellular resistance to viral infection. PLoS One 3:e2277. http://dx.doi.org/10.1371/journal.pone.0002277.
18. Reichelt M, Wang L, Sommer M, Perrino J, Nour AM, Sen N, Baiker A, Zerboni L, Arvin AM. 2011. Entrapment of viral capsids in nuclear PML cages is an intrinsic antiviral host defense against varicella-zoster virus. PLoS Pathog. 7:e1001266. http://dx.doi.org/10.1371/journal.ppat.1001266.
19. Pampin M, Simonin Y, Blondel B, Percherancier Y, Chelbi-Alix MK. 2006. Cross talk between PML and p53 during poliovirus infection: implications for antiviral defense. J. Virol. 80:8582-8592. http://dx.doi.org/10.1128/JVI.00031-06.
20. Doucas V, Ishov AM, Romo A, Juguilon H, Weitzman MD, Evans RM, Maul GG. 1996. Adenovirus replication is coupled with the dynamic properties of the PML nuclear structure. Genes Dev. 10:196-207. http://dx.doi.org/10.1101/gad.10.2.196.
21. Leppard KN, Emmott E, Cortese MS, Rich T. 2009. Adenovirus type 5 E4 Orf3 protein targets promyelocytic leukaemia (PML) protein nuclear domains for disruption via a sequence in PML isoform II that is predicted as a protein interaction site by bioinformatic analysis. J. Gen. Virol. 90:95-104. http://dx.doi.org/10.1099/vir.0.005512-0.
22. Everett RD, Maul GG. 1994. HSV-1 IE protein Vmw110 causes redistribution of PML. EMBO J. 13:5062-5069.
23. Maul GG, Everett RD. 1994. The nuclear location of PML, a cellular member of the C3HC4 zinc-binding domain protein family, is rearranged during herpes simplex virus infection by the C3HC4 viral protein ICP0. J. Gen. Virol. 75:1223-1233. http://dx.doi.org/10.1099/0022-1317-75-6-1223.
24. Everett RD, Parada C, Gripon P, Sirma H, Orr A. 2008. Replication of ICP0-null mutant herpes simplex virus type 1 is restricted by both PML and Sp100. J. Virol. 82:2661-2672. http://dx.doi.org/10.1128/JVI.02308-07.
25. Fraefel C, Bittermann AG, Bueler H, Heid I, Bachi T, Ackermann M. 2004. Spatial and temporal organization of adeno-associated virus DNA replication in live cells. J. Virol. 78:389-398. http://dx.doi.org/10.1128/JVI.78.1.389-398.2004.
26. Young PJ, Jensen KT, Burger LR, Pintel DJ, Lorson CL. 2002. Minute virus of mice NS1 interacts with the SMN protein, and they colocalize in novel nuclear bodies induced by parvovirus infection. J. Virol. 76:3892-3904. http://dx.doi.org/10.1128/JVI.76.8.3892-3904.2002.
27. Grieger JC, Choi VW, Samulski RJ. 2006. Production and characterization of adeno-associated viral vectors. Nat. Protoc. 1:1412-1428. http://dx.doi.org/10.1038/nprot.2006.207.
28. Mitchell AM, Li C, Samulski RJ. 2013. Arsenic trioxide stabilizes accumulations of adeno-associated virus virions at the perinuclear region, increasing transduction in vitro and in vivo. J. Virol. 87:4571-4583. http://dx.doi.org/10.1128/JVI.03443-12.
29. Wang ZG, Delva L, Gaboli M, Rivi R, Giorgio M, Cordon-Cardo C, Grosveld F, Pandolfi PP. 1998. Role of PML in cell growth and the retinoic acid pathway. Science 279:1547-1551. http://dx.doi.org/10.1126/science.279.5356.1547.
30. Thomas CE, Storm TA, Huang Z, Kay MA. 2004. Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors. J. Virol. 78:3110-3122. http://dx.doi.org/10.1128/JVI.78.6.3110-3122.2004.
31. Johnson JS, Samulski RJ. 2009. Enhancement of adeno-associated virus infection by mobilizing capsids into and out of the nucleolus. J. Virol. 83:2632-2644. http://dx.doi.org/10.1128/JVI.02309-08.
32. Arad U. 1998. Modified Hirt procedure for rapid purification of extrachromosomal DNA from mammalian cells. Biotechniques 24:760-762.
33. Davidoff AM, Ng CY, Zhou J, Spence Y, Nathwani AC. 2003. Sex significantly influences transduction of murine liver by recombinant adeno-associated viral vectors through an androgen-dependent pathway. Blood 102:480-488. http://dx.doi.org/10.1182/blood-2002-09-2889.
34. Zincarelli C, Soltys S, Rengo G, Rabinowitz JE. 2008. Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol. Ther. 16:1073-1080. http://dx.doi.org/10.1038/mt.2008.76.
35. Weidtkamp-Peters S, Lenser T, Negorev D, Gerstner N, Hofmann TG, Schwanitz G, Hoischen C, Maul G, Dittrich P, Hemmerich P. 2008. Dynamics of component exchange at PML nuclear bodies. J. Cell Sci. 121:2731-2743. http://dx.doi.org/10.1242/jcs.031922.
36. Nash K, Chen W, McDonald WF, Zhou X, Muzyczka N. 2007. Purification of host cell enzymes involved in adeno-associated virus DNA replication. J. Virol. 81:5777-5787. http://dx.doi.org/10.1128/JVI.02651-06.
37. Ni TH, McDonald WF, Zolotukhin I, Melendy T, Waga S, Stillman B, Muzyczka N. 1998. Cellular proteins required for adeno-associated virus DNA replication in the absence of adenovirus coinfection. J. Virol. 72:2777-2787.
38. Park J, Seo T, Kim H, Choe J. 2005. Sumoylation of the novel protein hRIPß is involved in replication protein A deposition in PML nuclear bodies. Mol. Cell. Biol. 25:8202-8214. http://dx.doi.org/10.1128/MCB.25.18.8202-8214.2005.
39. Van Damme E, Laukens K, Dang TH, Van Ostade X. 2010. A manually curated network of the PML nuclear body interactome reveals an important role for PML-NBs in SUMOylation dynamics. Int. J. Biol. Sci. 6:51-67. http://dx.doi.org/10.7150/ijbs.6.51.
40. Christensen J, Tattersall P. 2002. Parvovirus initiator protein NS1 and RPA coordinate replication fork progression in a reconstituted DNA replication system. J. Virol. 76:6518-6531. http://dx.doi.org/10.1128/JVI.76.13.6518-6531.2002.
41. Berscheminski J, Groitl P, Dobner T, Wimmer P, Schreiner S. 2013. The adenoviral oncogene E1A-13S interacts with a specific isoform of the tumor suppressor PML to enhance viral transcription. J. Virol. 87:965-977. http://dx.doi.org/10.1128/JVI.02023-12.
42. Nojima T, Oshiro-Ideue T, Nakanoya H, Kawamura H, Morimoto T, Kawaguchi Y, Kataoka N, Hagiwara M. 2009. Herpesvirus protein ICP27 switches PML isoform by altering mRNA splicing. Nucleic Acids Res. 37:6515-6527. http://dx.doi.org/10.1093/nar/gkp633.
43. Cuchet D, Sykes A, Nicolas A, Orr A, Murray J, Sirma H, Heeren J, Bartelt A, Everett RD. 2011. PML isoforms I and II participate in PML-dependent restriction of HSV-1 replication. J. Cell Sci. 124:280-291. http://dx.doi.org/10.1242/jcs.075390.
44. Geoffroy MC, Epstein AL, Toublanc E, Moullier P, Salvetti A. 2004. Herpes simplex virus type 1 ICP0 protein mediates activation of adeno-associated virus type 2 rep gene expression from a latent integrated form. J. Virol. 78:10977-10986. http://dx.doi.org/10.1128/JVI.78.20.10977-10986.2004.
45. Beaton A, Palumbo P, Berns KI. 1989. Expression from the adenoassociated virus p5 and p19 promoters is negatively regulated in trans by the rep protein. J. Virol. 63:4450-4454.
46. Chang LS, Shi Y, Shenk T. 1989. Adeno-associated virus P5 promoter contains an adenovirus E1A-inducible element and a binding site for the major late transcription factor. J. Virol. 63:3479-3488.
47. Hermonat PL, Santin AD, Batchu RB, Zhan D. 1998. The adenoassociated virus Rep78 major regulatory protein binds the cellular TATA-binding protein in vitro and in vivo. Virology 245:120-127. http://dx.doi.org/10.1006/viro.1998.9144.
48. Pereira DJ, McCarty DM, Muzyczka N. 1997. The adeno-associated virus (AAV) Rep protein acts as both a repressor and an activator to regulate AAV transcription during a productive infection. J. Virol. 71:1079-1088.
49. Weger S, Wendland M, Kleinschmidt JA, Heilbronn R. 1999. The adeno-associated virus type 2 regulatory proteins rep78 and rep68 interact with the transcriptional coactivator PC4. J. Virol. 73:260-269.